GLP-1 Vision Loss (Ozempic / Wegovy NAION) Lawsuit

What NAION is — and why sudden vision loss is an emergency

NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front of the optic nerve is suddenly interrupted — a stroke-like injury to the nerve that carries sight from the eye to the brain. The vision loss is usually painless, strikes one eye, and is often first noticed on waking. In most cases it is permanent: there is no proven treatment that reliably restores the lost vision. After glaucoma, NAION is one of the most common causes of optic-nerve blindness in older adults.

The GLP-1 connection

GLP-1 receptor agonists are among the most widely prescribed medicines in the United States. Semaglutide is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight loss. Beginning in 2024, researchers and eye doctors started reporting an association between these drugs and NAION — raising the question of whether a medication taken by millions could be triggering a rare but devastating form of sudden blindness.

What the Harvard study found

Hathaway and colleagues at Harvard Medical School published a study in JAMA Ophthalmology (2024) examining patients prescribed semaglutide. Among people with type 2 diabetes, those on semaglutide had a markedly higher risk of NAION — a hazard ratio of 4.28 — and among overweight or obese patients the hazard ratio was 7.64. The authors were careful to note that this was a single-center, observational study and that further research is needed to establish causation. A later, much larger population study found a smaller association (an incidence-rate ratio of about 1.32). The science is still developing — but the signal was strong enough to prompt regulatory attention, label discussions, and litigation.

Which drugs are involved

The MDL is organized around GLP-1 receptor agonists as a class. The strongest evidence to date concerns semaglutide — Ozempic, Wegovy, and Rybelsus. Related medications in the same class, including tirzepatide (Mounjaro and Zepbound), are part of the broader conversation and are being watched closely, though the core published research centers on semaglutide. If you took any GLP-1 drug and then lost vision, it is worth having your case reviewed.

The MDL: where the cases stand

In December 2025, the U.S. Judicial Panel on Multidistrict Litigation created In re GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Marston. The panel kept these vision-loss claims separate from an earlier GLP-1 gastrointestinal-injury litigation, concluding that NAION is a distinct injury deserving its own proceeding. The court held a Science Day — a session to educate the judge on the underlying medicine — on June 2, 2026, and roughly 110 cases were pending as of that month, with more being filed.

Who may qualify

You may have a claim worth investigating if all of the following are true:

• You took a GLP-1 drug — such as Ozempic, Wegovy, or Rybelsus (semaglutide) — for diabetes or weight loss.
• You were later diagnosed with NAION, or suffered sudden, painless vision loss in one eye (often first noticed on waking).
• An eye doctor or ophthalmologist examined and documented the vision loss.

What proof matters

These cases are built on records that already exist. Pharmacy and prescription records establish that you took a GLP-1 drug and for how long. Ophthalmology and hospital records document the NAION diagnosis. Timing matters: research suggests the risk is highest in the first year after starting the drug, so the sequence between starting a GLP-1 medication and losing vision can be important evidence.

An honest word on what this means

Every case is different, and no lawsuit or study guarantees any outcome or recovery; whether a drug caused a specific person's vision loss depends on the medical facts. People's Justice is not a law firm and does not provide legal advice — we investigate potential claims and connect people who may qualify with independent attorneys who handle GLP-1 and pharmaceutical cases. Our summary is informed by primary sources, including the study in JAMA Ophthalmology and the orders of the U.S. Judicial Panel on Multidistrict Litigation.